definiens: within the meaning of the Private Securities Litigation Reform Act of 1995 . Because such statements are subject to risks anduncertainties, actual results may differ materially from those expressed or implied by such forward - looking statements . Suchstatements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits ofRDEA806, RDEA594, RDEA427, RDEA119, RDEA436 and our other compounds and the timing and results of ourpreclinical, clinical and other studies . Risks that contribute to the uncertain nature of the forward - looking statementsinclude risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays incommencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, andrisks related to the outcome of our business development activities . These and other risks and uncertainties are describedmore fully in our most recently filed SEC documents, including our Annual Report on Form 10 - K and our Quarterly Reportson Form 10 - Q, under the headings All forward - looking statements contained in this press release speak onlyas of the date on which they were made . We undertake no obligation to update such statements to reflect events that occur orcircumstances that exist after the date on which they were made